Atomo Diagnostics Ltd
ASX:AT1

Watchlist Manager
Atomo Diagnostics Ltd Logo
Atomo Diagnostics Ltd
ASX:AT1
Watchlist
Price: 0.021 AUD 5% Market Closed
Market Cap: 14.4m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AT1 stock under the Base Case scenario is 0.016 AUD. Compared to the current market price of 0.021 AUD, Atomo Diagnostics Ltd is Overvalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AT1 Relative Value
Base Case
0.016 AUD
Overvaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
93
vs Industry
40
Median 3Y
3.2
Median 5Y
5
Industry
2.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2
Median 5Y
-3.4
Industry
22
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-10.4
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-6
Industry
20
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
76
vs Industry
50
Median 3Y
1.4
Median 5Y
1.6
Industry
2.2
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
92
vs Industry
48
Median 3Y
2.3
Median 5Y
3
Industry
2.4
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
93
vs Industry
43
Median 3Y
5.5
Median 5Y
9.2
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-2.7
Industry
11.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-2.7
Industry
15.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-7
Industry
14.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-4.1
Industry
18
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
82
vs Industry
45
Median 3Y
1.5
Median 5Y
1.7
Industry
1.8
More Details

Multiples Across Competitors

AT1 Competitors Multiples
Atomo Diagnostics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Atomo Diagnostics Ltd
ASX:AT1
13.4m AUD 3.1 -2.1 -1.9 -1.9
US
Abbott Laboratories
NYSE:ABT
208.7B USD 4.9 15.5 20.1 28.9
US
Intuitive Surgical Inc
NASDAQ:ISRG
185B USD 21.2 74.7 60.2 73.2
US
Boston Scientific Corp
NYSE:BSX
154.8B USD 8.8 76.1 35.9 49.9
US
Stryker Corp
NYSE:SYK
148.6B USD 6.4 52 25.7 30.9
IE
Medtronic PLC
NYSE:MDT
114.8B USD 3.4 24.6 13.7 19.6
DE
Siemens Healthineers AG
XETRA:SHL
52.3B EUR 2.3 25 14 19.5
US
Becton Dickinson and Co
NYSE:BDX
51.8B USD 2.5 34.1 13.5 25.2
US
Edwards Lifesciences Corp
NYSE:EW
44.8B USD 8.1 10.7 24.5 27
US
IDEXX Laboratories Inc
NASDAQ:IDXX
41.9B USD 10.7 46.8 33.2 37.1
US
Resmed Inc
NYSE:RMD
37.7B USD 7.5 28.7 20.5 23.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Atomo Diagnostics Ltd
ASX:AT1
Average EV/EBITDA: 26.1
Negative Multiple: -1.9 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
20.1
13%
1.5
US
Intuitive Surgical Inc
NASDAQ:ISRG
60.2
24%
2.5
US
Boston Scientific Corp
NYSE:BSX
35.9
21%
1.7
US
Stryker Corp
NYSE:SYK
25.7
12%
2.1
IE
Medtronic PLC
NYSE:MDT
13.7
7%
2
DE
Siemens Healthineers AG
XETRA:SHL
14
14%
1
US
Becton Dickinson and Co
NYSE:BDX
13.5
11%
1.2
US
Edwards Lifesciences Corp
NYSE:EW
24.5
12%
2
US
IDEXX Laboratories Inc
NASDAQ:IDXX
33.2
12%
2.8
US
Resmed Inc
NYSE:RMD
20.5
12%
1.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Atomo Diagnostics Ltd
ASX:AT1
Average EV/EBIT: 33.5
Negative Multiple: -1.9 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
28.9
22%
1.3
US
Intuitive Surgical Inc
NASDAQ:ISRG
73.2
26%
2.8
US
Boston Scientific Corp
NYSE:BSX
49.9
31%
1.6
US
Stryker Corp
NYSE:SYK
30.9
16%
1.9
IE
Medtronic PLC
NYSE:MDT
19.6
15%
1.3
DE
Siemens Healthineers AG
XETRA:SHL
19.5
19%
1
US
Becton Dickinson and Co
NYSE:BDX
25.2
28%
0.9
US
Edwards Lifesciences Corp
NYSE:EW
27
12%
2.3
US
IDEXX Laboratories Inc
NASDAQ:IDXX
37.1
12%
3.1
US
Resmed Inc
NYSE:RMD
23.2
14%
1.7

See Also

Summary
AT1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
AT1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AT1 stock valuation using valuation multiples.
Wall Street Estimates
AT1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AT1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.